ANEB — Anebulo Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $94.08m
- $83.73m
- 33
- 12
- 94
- 43
Annual cashflow statement for Anebulo Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -30.3 | -6.83 | -11.7 | -8.2 | -8.48 |
| Non-Cash Items | 26.8 | 0.481 | 0.885 | 0.91 | 1.83 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.45 | 0.908 | 1.16 | -0.799 | 0.306 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -4.87 | -5.44 | -9.68 | -8.09 | -6.35 |
| Financing Cash Flow Items | -0.822 | 0 | -0.317 | -0.062 | -0.117 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 21.8 | 0 | 6.38 | -0.062 | 14.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 17 | -5.44 | -3.3 | -8.15 | 8.53 |